Loading clinical trials...

COMPLETED

Fibroblast Growth Factor 23 and Sclerostin in Relation to Calcium in COVID-19 Patients

Serum Levels of Fibroblast Growth Factor 23 and Sclerostin in Relation to Serum Calcium Level in COVID 19 Patients

NCT05275491•Aswan University Hospital

Summary

Hypocalcemia is associated with COVID-19 patients and is linked to poor prognosis, Fibroblast growth factor 23 (FGF23) and Sclerostin inhibit vitamin D activation and are linked to hypocalcemia. Levels of FGF23 and Sclerostin in COVID-19 patients will be detected and correlated to calcium levels.

Detailed Description

COVID 19 is a current worldwide pandemic caused by severe acute respiratory syndrome coronavirus 2 "SARS-CoV-2". Hypovitaminosis D and hypocalcaemia have been reported to be associated with COVID 19 infection, they are considered good biomarkers of clinical severity of COVID 19. Poor prognosis related to hypocalcemia is increased in elderly patients. Fibroblast growth factor 23 and sclerostin are secreted from the bone, they decrease active vitamin D levels. Their levels and their relation to calcium levels in COVID-19 patients will be detected.

Eligibility

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•Positive COVID 19 (Mild to moderate - severe to critical).

Exclusion Criteria

•known diagnosis of CKD.
•Known parathyroid disease.
•Use of phosphate binder therapy within the past 3 months.
•Use of calcium therapy within the past 3 months
•Treatment with 25(OH) vitamin D or 1,25 (OH)(2) D
•Underlying metabolic bone disease.
•Underlying renal phosphate wasting disorder.

Locations (1)

Aswan University hospital

Aswān, Egypt

Key Dates

Start Date

May 1, 2022

Primary Completion Date

January 1, 2023

Completion Date

February 1, 2023

Last Updated

February 14, 2023

Enrollment

ACTUAL participants

Conditions

COVID-19

Interventions

Calcium

DIAGNOSTIC_TEST

Fibroblast growth factor 23

DIAGNOSTIC_TEST

Sclerostin

DIAGNOSTIC_TEST

parathyroid hormone

DIAGNOSTIC_TEST

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162

COVID-19

View study

RECRUITINGNA

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

NCT06082518

Post COVID-19 ConditionPost-COVID-19 Syndrome+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 14, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Fibroblast Growth Factor 23 and Sclerostin in Relation to Calcium in COVID-19 Patients

Inclusion Criteria

Exclusion Criteria

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Dime La VerDAD: Verify, Debunk, and Disseminate

Positron Emission Tomography (PET) Imaging of Thrombosis